In this double-blind, placebo-controlled trial 120 adults with moderate to severe diverticular disease (DD) were randomised to receive either Symprove or a matching placebo drink for three months.
The study concluded that Symprove had a significant benefit on
Faecal calprotectin levels were measured before and after treatment. Reductions in calprotectin levels (intestinal inflammation) were observed in the majority (75%) of male patients with DD. The decrease in intestinal inflammation was significantly greater than in the placebo group.
Reductions in calprotectin levels (intestinal inflammation) were observed in the majority (75%) of male patients with DD
Professor Ingvar Bjarnason, consultant gastroenterology and principal investigator of the study.
‘These are exciting and significant results as up to now there has been no proven effective treatment for patients.’
The independent study was carried out at Kings College Hospital London by Dr Savvas Papagrigoriadis and Professor Ingvar Bjarnason. The results of the study were presented at the leading world Gastroenterology congress, Digestive Disease Week, San Diego, in May 2016.
Welcome to Symprove Holdings Limited scientific website.
To access this site, please confirm that you are a healthcare professional, scientist or journalist.